宿主-病原体蛋白质-蛋白质相互作用的共价抑制降低了肺炎菌的传染性
Yuhan Lyu1, Fan Yang1, Bharathi Sundaresh2
1Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, Massachusetts 02467, United States.
新型蛋白质-蛋白质相互作用抑制剂向Streptococcus pneumoniae毒性因子 PspC. 这种方法减少了细菌的附着性,并增强了免疫反应,为抗生素耐药性提供了新的策略.
科学领域:
- 微生物学 微生物学
- 药物发现 药物发现 药物发现
- 免疫学 免疫学 免疫学
背景情况:
- 抗生素耐药性需要新的抗菌策略,具有新的作用机制.
- 肺炎链球菌利用表面蛋白质PspC作为一个关键的毒性因素.
- 通过与人体补充因子H (hFH) 相互作用,抑制宿主免疫力并促进细菌粘附,PSPC促进了感染.
研究的目的:
- 探索蛋白质-蛋白质相互作用 (PPI) 抑制作为一种新的治疗方法来对抗细菌感染.
- 开发针对Streptococcus pneumoniae中PspC-hFH相互作用的特定抑制剂.
主要方法:
- 补充控制蛋白域9 (CCP9) 的hFH的重组表达抑制PSPC-hFH结合.
- 对活肺炎球菌细胞的抑制的证明.
- 开发用于持续PspC抑制的共价CCP9抑制剂.
主要成果:
- CCP9域有效抑制了PSPC-hFH相互作用,代表了这种途径的第一个药理干预.
- 抑制PPI可以减少肺炎球菌与上皮细胞的附着.
- 抑制剂使S. pneumoniae的D39菌株对声化重新敏感.
- 共价性CCP9抑制剂实现了长期的PSPC抑制,具有较低的纳米分子强度.
结论:
- 抑制蛋白与蛋白相互作用是开发新抗菌疗法的有希望的策略.
- 协同抑制剂提供了一种强大且持续的方法来准像PSPC这样的细菌毒性因子.
- 这项研究提供了一个新的药理学工具,用于对抗Streptococcus pneumoniae感染并克服抗生素耐药性.
更多相关视频
12:21A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Published on: September 28, 2022
06:05Using the Overlay Assay to Qualitatively Measure Bacterial Production of and Sensitivity to Pneumococcal Bacteriocins
Published on: September 30, 2014
相关概念视频
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Protein-protein Interfaces
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
